CN1795901A - 一种清热解毒、利湿退黄的药物 - Google Patents
一种清热解毒、利湿退黄的药物 Download PDFInfo
- Publication number
- CN1795901A CN1795901A CN 200410081586 CN200410081586A CN1795901A CN 1795901 A CN1795901 A CN 1795901A CN 200410081586 CN200410081586 CN 200410081586 CN 200410081586 A CN200410081586 A CN 200410081586A CN 1795901 A CN1795901 A CN 1795901A
- Authority
- CN
- China
- Prior art keywords
- medicine
- extract
- parts
- polyethylene glycol
- clearing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 90
- 206010023126 Jaundice Diseases 0.000 title claims abstract description 27
- 229940079593 drug Drugs 0.000 title description 22
- 231100000331 toxic Toxicity 0.000 title description 3
- 230000002588 toxic effect Effects 0.000 title description 3
- 239000000284 extract Substances 0.000 claims description 94
- 241000628997 Flos Species 0.000 claims description 30
- 239000002202 Polyethylene glycol Substances 0.000 claims description 26
- 229920001223 polyethylene glycol Polymers 0.000 claims description 26
- 231100000614 poison Toxicity 0.000 claims description 20
- 239000003440 toxic substance Substances 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 239000006187 pill Substances 0.000 claims description 16
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims description 13
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims description 13
- 229960003321 baicalin Drugs 0.000 claims description 13
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims description 13
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 10
- 229960003511 macrogol Drugs 0.000 claims description 10
- 239000007901 soft capsule Substances 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 6
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 6
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 6
- 239000008158 vegetable oil Substances 0.000 claims description 6
- 108010010803 Gelatin Proteins 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 4
- 239000007902 hard capsule Substances 0.000 claims description 4
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 229920002472 Starch Polymers 0.000 claims description 3
- 239000007766 cera flava Substances 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000004615 ingredient Substances 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 235000019698 starch Nutrition 0.000 claims description 3
- 239000006196 drop Substances 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 abstract description 21
- 108010082126 Alanine transaminase Proteins 0.000 abstract description 21
- 241000205585 Aquilegia canadensis Species 0.000 abstract description 2
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 abstract 1
- 235000003097 Artemisia absinthium Nutrition 0.000 abstract 1
- 240000001851 Artemisia dracunculus Species 0.000 abstract 1
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 abstract 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract 1
- 235000018958 Gardenia augusta Nutrition 0.000 abstract 1
- 244000111489 Gardenia augusta Species 0.000 abstract 1
- 241000207929 Scutellaria Species 0.000 abstract 1
- 239000001138 artemisia absinthium Substances 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 238000002360 preparation method Methods 0.000 description 23
- 230000000694 effects Effects 0.000 description 22
- 238000000034 method Methods 0.000 description 19
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 16
- 210000002966 serum Anatomy 0.000 description 14
- 208000006454 hepatitis Diseases 0.000 description 13
- 239000000706 filtrate Substances 0.000 description 12
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 10
- 239000007788 liquid Substances 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 231100000283 hepatitis Toxicity 0.000 description 7
- 208000002672 hepatitis B Diseases 0.000 description 7
- 230000003908 liver function Effects 0.000 description 7
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 238000004321 preservation Methods 0.000 description 6
- 206010008909 Chronic Hepatitis Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 231100000753 hepatic injury Toxicity 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 238000004064 recycling Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000008865 yin zhi huang Substances 0.000 description 4
- 208000005176 Hepatitis C Diseases 0.000 description 3
- 241000594182 Sarcophaga sigma Species 0.000 description 3
- 108090000340 Transaminases Proteins 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000002443 hepatoprotective effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000012567 medical material Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 102000014898 transaminase activity proteins Human genes 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- PAFLSMZLRSPALU-MRVPVSSYSA-N (2R)-3-(3,4-dihydroxyphenyl)lactic acid Chemical compound OC(=O)[C@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-MRVPVSSYSA-N 0.000 description 2
- 239000001074 1-methoxy-4-[(E)-prop-1-enyl]benzene Substances 0.000 description 2
- PAFLSMZLRSPALU-QMMMGPOBSA-N Danshensu Natural products OC(=O)[C@@H](O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-QMMMGPOBSA-N 0.000 description 2
- 241000218628 Ginkgo Species 0.000 description 2
- 235000011201 Ginkgo Nutrition 0.000 description 2
- 235000008100 Ginkgo biloba Nutrition 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- PAFLSMZLRSPALU-UHFFFAOYSA-N Salvianic acid A Natural products OC(=O)C(O)CC1=CC=C(O)C(O)=C1 PAFLSMZLRSPALU-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 210000005252 bulbus oculi Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 2
- 239000000312 peanut oil Substances 0.000 description 2
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 2
- 229960002695 phenobarbital Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 1
- 206010008609 Cholangitis sclerosing Diseases 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- IBFYXTRXDNAPMM-BVTMAQQCSA-N Geniposide Chemical compound O([C@@H]1OC=C([C@@H]2[C@H]1C(=CC2)CO)C(=O)OC)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O IBFYXTRXDNAPMM-BVTMAQQCSA-N 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 206010061998 Hepatic lesion Diseases 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 206010019754 Hepatitis cholestatic Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HTBWBWWADZJXID-TXEJJXNPSA-N Wuweizisu C Chemical compound COC1=C2C=3C(OC)=C4OCOC4=CC=3C[C@H](C)[C@H](C)CC2=CC2=C1OCO2 HTBWBWWADZJXID-TXEJJXNPSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229960001091 chenodeoxycholic acid Drugs 0.000 description 1
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 230000001989 choleretic effect Effects 0.000 description 1
- 231100000838 cholestatic hepatitis Toxicity 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- ZOOODBUHSVUZEM-UHFFFAOYSA-N ethoxymethanedithioic acid Chemical compound CCOC(S)=S ZOOODBUHSVUZEM-UHFFFAOYSA-N 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- HTBWBWWADZJXID-UHFFFAOYSA-N gamma-schisandrin Natural products COC1=C2C=3C(OC)=C4OCOC4=CC=3CC(C)C(C)CC2=CC2=C1OCO2 HTBWBWWADZJXID-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 235000011837 pasties Nutrition 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 201000000742 primary sclerosing cholangitis Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000009286 sanguis draxonis Substances 0.000 description 1
- 208000010157 sclerosing cholangitis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000004799 sedative–hypnotic effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
- 229960001661 ursodiol Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012991 xanthate Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 剂量(g/kg) | 鼠数(只) | ALT(nmol/s.L) | AST(nmol/s.L) |
对照组模型组本发明药物组高剂量本发明药物组中剂量本发明药物组低剂量不含聚乙二醇的对比药物茵栀黄口服液 | 0.250.510.251.5 | 10101010101010 | 181.52±20.31451.21±24.14▲289.44±36.35***299.51±37.22***304.86±54.04***345.65±37.74**340.54±27.64** | 161.24±40.54431.91±29.55▲201.67±27.81***210.59±41.67***215.83±44.24***254.87±50.14**247.57±33.23** |
组别 | 剂量(g/kg) | 鼠数(只) | ALT(nmol/s.L) | AST(nmol/s.L) |
对照组模型组本发明药物组高剂量本发明药物组中剂量本发明药物组低剂量不含聚乙二醇的对比药物茵栀黄口服液 | 0.250.510.251.5 | 10101010101010 | 199.14±27.54422.57±37.47▲311.58±42.47**320.58±44.21**334.61±33.07**365.87±42.69*355.47±39.41* | 187.58±30.14401.14±38.47▲271.44±32.49**284.88±50.31**297.81±47.26**254.87±50.85*263.24±34.67* |
组别 | 剂量(g/kg) | 鼠数(只) | 总胆红素(nmol/L) | 结合胆红素(nmol/L) |
对照组模型组本发明药物组高剂量本发明药物组中剂量本发明药物组低剂量不含聚乙二醇的对比药物茵栀黄口服液 | 0.250.510.251.5 | 10101010101010 | 6.75±3.4538.24±12.21▲8.46±6.58***10.53±8.26***13.28±9.35***20.18±10.37**17.63±9.48** | 2.18±1.0410.38±8.27▲3.01±1.34***3.17±1.09***4.37±2.11***6.43±2.49**4.82±1.97** |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410081586 CN1795901B (zh) | 2004-12-27 | 2004-12-27 | 一种清热解毒、利湿退黄的药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410081586 CN1795901B (zh) | 2004-12-27 | 2004-12-27 | 一种清热解毒、利湿退黄的药物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1795901A true CN1795901A (zh) | 2006-07-05 |
CN1795901B CN1795901B (zh) | 2011-02-09 |
Family
ID=36817356
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410081586 Expired - Fee Related CN1795901B (zh) | 2004-12-27 | 2004-12-27 | 一种清热解毒、利湿退黄的药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1795901B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105288112A (zh) * | 2015-11-27 | 2016-02-03 | 黑龙江众生生物工程有限公司 | 一种茵陈清热利湿片及其制备方法 |
CN105362599A (zh) * | 2015-11-27 | 2016-03-02 | 黑龙江众生生物工程有限公司 | 一种火殃勒清热解毒片及其制备方法 |
CN105395886A (zh) * | 2015-11-27 | 2016-03-16 | 黑龙江众生生物工程有限公司 | 一种火殃勒清热解暑片及其制备方法 |
CN105770001A (zh) * | 2016-04-27 | 2016-07-20 | 周德珍 | 用于预防胆汁淤积性黄疽并发症的颗粒剂及其制备方法 |
-
2004
- 2004-12-27 CN CN 200410081586 patent/CN1795901B/zh not_active Expired - Fee Related
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105288112A (zh) * | 2015-11-27 | 2016-02-03 | 黑龙江众生生物工程有限公司 | 一种茵陈清热利湿片及其制备方法 |
CN105362599A (zh) * | 2015-11-27 | 2016-03-02 | 黑龙江众生生物工程有限公司 | 一种火殃勒清热解毒片及其制备方法 |
CN105395886A (zh) * | 2015-11-27 | 2016-03-16 | 黑龙江众生生物工程有限公司 | 一种火殃勒清热解暑片及其制备方法 |
CN105770001A (zh) * | 2016-04-27 | 2016-07-20 | 周德珍 | 用于预防胆汁淤积性黄疽并发症的颗粒剂及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN1795901B (zh) | 2011-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1943610A (zh) | 一种用于跌打损伤、瘀血肿痛等疾病的中药制剂 | |
CN1775261A (zh) | 明目地黄制剂及新的制备方法 | |
CN1895546A (zh) | 具有治疗和保健功能的杞多糖药物组合物 | |
CN1748748A (zh) | 孕妇金花制剂及新的制备方法 | |
CN1795901B (zh) | 一种清热解毒、利湿退黄的药物 | |
CN1775263A (zh) | 杞菊地黄制剂及新的制备方法 | |
CN1130212C (zh) | 治疗痞症的药物及其制备方法 | |
CN1679887A (zh) | 一种治疗肝炎的中药组合物 | |
CN1748741A (zh) | 金花消痤制剂及新的制备方法 | |
CN1698775A (zh) | 含有拉米夫定的药物组合物 | |
CN1199683C (zh) | 一种降血脂和延缓衰老药物组合物及药物 | |
CN1775238A (zh) | 消炎止痢制剂及新的制备方法 | |
CN1957959A (zh) | 治疗慢性咽炎、抗过敏的药物及其制备方法 | |
CN1291727C (zh) | 一种治疗心脑血管疾病的中药组合物及其制备方法和用途 | |
CN1590396A (zh) | 一种胡黄连总苷提取物及其在制备肝病药物中的应用和制备方法 | |
CN1634241A (zh) | 治疗心脑血管疾病的复方三七制剂及其制备方法 | |
CN1126558C (zh) | 一种治疗红斑狼疮所致肾脏损害的药物 | |
CN101057906B (zh) | 一种治疗肝炎的中药组合物及其药物制剂以及其应用 | |
CN1212150C (zh) | 治疗病毒性肝炎的药物及制备方法 | |
CN1823937A (zh) | 香连制剂及新的制备方法 | |
CN1063077C (zh) | 一种降血脂的中药药剂及其制法 | |
CN1824117A (zh) | 调经补血制剂及新的制备方法 | |
CN1799602A (zh) | 一种益气滋阴的药物滴丸及其制备方法 | |
CN1839931A (zh) | 一种治疗心脑血管疾病的药物组合物及其制备方法 | |
CN1742798A (zh) | 五海瘿瘤制剂及新的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: QINGHAI REACH PHARMACEUTICAL (GROUP) CO., LTD. Free format text: FORMER OWNER: LI WENJUN Effective date: 20111017 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 610041 CHENGDU, SICHUAN PROVINCE TO: 810007 XINING, QINGHAI PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20111017 Address after: 810007 No. 18, Dongxin Road, Xining economic and Technological Development Zone, Qinghai, China Patentee after: Qingdao Reach Pharmaceutical (Group) Co., Ltd. Address before: 610041 Sichuan, Chengdu, Wuhou District, wash Bridge Street, building 7, No. 12 Patentee before: Li Wenjun |
|
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110209 Termination date: 20121227 |